

Tivozanib TIVO-3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Tivozanib TIVO-3

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Adult patients with relapsed or refractory advanced RCC following ≥ 2 prior systemic therapies

Experimental Arm: Tivozanib

Control Arm: Sorafenib

